Enanta Pharmaceuticals, Inc. (ENTA) on Wednesday said its Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH), dubbed ARGON-1, achieved its primary and secondary endpoints.
from RTT - Biotech https://ift.tt/2mSDQEU
via IFTTT
No comments:
Post a Comment